Effect of Remdesivir in treatment of COVID-19

Phase 4

• Conditions: Covid-19.; Covid-19, virus identified; U07.1

• Registration Number: IRCT20210324050760N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Blood oxygen saturation<93% in room air or patients with patients in need of supportive oxygen or ventilation or
Patients with pulmonary infiltration in radiological studies

Exclusion Criteria

Alanine aminotransferase and Aspartate aminotransferase rising more than 5 times the upper limit of normal
Glomerular filtration rate less than 30ml/minute(according to Cockroft-Gault formula)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality or discharge. Timepoint: End of hospitalization period. Method of measurement: Patient file.;Hospitalization period. Timepoint: Hospitalization to discharge period. Method of measurement: Patient file.;ICU admission. Timepoint: From Hospitalization to discharge. Method of measurement: Patient file.;Clinical symptoms. Timepoint: From hospitalization to discharge. Method of measurement: Interview and examination.;Laboratory data. Timepoint: From hospitalization to discharge. Method of measurement: Laboratory.